<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915107</url>
  </required_header>
  <id_info>
    <org_study_id>SO IX OCT STEMI</org_study_id>
    <nct_id>NCT02915107</nct_id>
  </id_info>
  <brief_title>The SORT OUT IX STEMI OCT Trial</brief_title>
  <acronym>OCT STEMI SOIX</acronym>
  <official_title>Randomized Comparison of Vascular Healing of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent With a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients With ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) IX&#xD;
      STEMI OCT is to compare early vascular healing of the polymer-free Biolimus-eluting&#xD;
      BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting ORSIRO stent in patients with&#xD;
      ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary&#xD;
      intervention (PCI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SORT OUT IX STEMI OCT is a randomized 1:1 study comparing the polymer-free Biolimus-eluting&#xD;
      BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting ORSIRO stent patients with&#xD;
      STEMI treated with primary PCI.&#xD;
&#xD;
      Vascular healing index (uncovered stent struts, malapposed stent struts, maximal intima&#xD;
      coverage and accumulated extra-stent lumen volume) assessed with optical coherence tomography&#xD;
      (OCT) 1 month after primary PCI.&#xD;
&#xD;
      Patients will be enrolled by the investigators and randomly allocated to treatment groups&#xD;
      after diagnostic coronary angiography and before primary PCI. A web based Trial Partner&#xD;
      randomization system will be used.&#xD;
&#xD;
      OCT will be performed with the frequency-domain OPTIS OCT system and Dragonflyâ„¢ Imaging&#xD;
      Catheter during the index procedure and after 1 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular healing index (uncovered stent struts, malapposed stent struts, maximal intima coverage and accumulated extra-stent lumen volume) assessed with optical coherence tomography (OCT) 1 month after primary PCI.</measure>
    <time_frame>Primary endpoint assessed after 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Biofreedom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Biofreedom BioFreedom stent at index procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator: Orsiro Orsiro stent at index procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioFreedom</intervention_name>
    <description>PCI with BioFreedom</description>
    <arm_group_label>Biofreedom</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro</intervention_name>
    <description>PCI with BioFreedom</description>
    <arm_group_label>Orsiro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years or over with STEMI, requiring treatment with a drug-eluting&#xD;
             stent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  life expectancy of less than one year; an allergy to aspirin, clopidogrel, ticagrelor,&#xD;
             prasugral, biolimus or sirolimus; participation in another randomized trial; chronic&#xD;
             renal disease; or inability to provide written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisette Okkels Jensen, MD DMSci PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8210</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Lisette Okkels Jensen</investigator_full_name>
    <investigator_title>MD DMSci</investigator_title>
  </responsible_party>
  <keyword>drug eluting stents</keyword>
  <keyword>coronary vascular healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

